KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2016 - 2023)

Historic Short-Term Debt issuances for Teva Pharmaceutical Industries (TEVA) over the last 12 years, with Q3 2023 value amounting to $700.0 million.

  • Teva Pharmaceutical Industries' Short-Term Debt issuances changed N/A to $700.0 million in Q3 2023 from the same period last year, while for Dec 2024 it was $700.0 million, marking a year-over-year decrease of 2222.22%. This contributed to the annual value of $700.0 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q3 2023, Teva Pharmaceutical Industries' Short-Term Debt issuances is $700.0 million.
  • Teva Pharmaceutical Industries' 5-year Short-Term Debt issuances high stood at $700.0 million for Q3 2023, and its period low was -$1.0 million during Q1 2019.
  • Over the past 4 years, Teva Pharmaceutical Industries' median Short-Term Debt issuances value was $200.0 million (recorded in 2021), while the average stood at $245.6 million.
  • Its Short-Term Debt issuances has fluctuated over the past 5 years, first soared by 990000.0% in 2019, then tumbled by 3730.41% in 2021.
  • Over the past 4 years, Teva Pharmaceutical Industries' Short-Term Debt issuances (Quarter) stood at $404.0 million in 2019, then dropped by 21.04% to $319.0 million in 2020, then crashed by 37.3% to $200.0 million in 2021, then skyrocketed by 250.0% to $700.0 million in 2023.
  • Its Short-Term Debt issuances was $700.0 million in Q3 2023, compared to $200.0 million in Q4 2021 and $319.0 million in Q4 2020.